• KOL
    • Metastatic Melanoma
    • Steven Aaron Rosenberg
    • Steven Aaron Rosenberg: Influence Statistics

      Steven Aaron Rosenberg

      Steven Aaron Rosenberg

      Show email address

      Surgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland. | Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Steven Aaron Rosenberg:Expert Impact

      Concepts for whichSteven Aaron Rosenberghas direct influence:Metastatic melanoma,Tumor cells,Adoptive transfer,Adoptive immunotherapy,Killer cells,Infiltrating lymphocytes,Patients metastatic melanoma,Tumor infiltrating.

      Steven Aaron Rosenberg:KOL impact

      Concepts related to the work of other authors for whichfor which Steven Aaron Rosenberg has influence:Tumor cells,Cancer immunotherapy,Gene therapy,Metastatic melanoma,Renal cell,Immune response.

      KOL Resume for Steven Aaron Rosenberg

      Year
      2022

      Surgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.

      2021

      Surgery Branch, National Cancer Institute, Bethesda, Maryland.

      NCI, Bethesda, MD, USA

      2020

      Surgery Branch, Center for Cancer Research, National Cancer Istitute, NIH, Bethesda, MD.

      NCI, N Bethesda, Maryland, USA

      National Cancer Institute at the National Institutes of Health, Bethesda, MD;

      2019

      Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

      National Institutes of Health, Bethesda, MD.

      2018

      Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA.

      National Cancer Institute, NIH, Maryland.

      2017

      James N. Kochenderfer, Robert P.T. Somerville, Tangying Lu, Victoria Shi, Stephanie L. Goff, James C. Yang, Richard M. Sherry, Christopher A. Klebanoff, Udai S. Kammula, Constance M. Yuan, Mark J. Roschewski, Steven A. Feldman, Lori McIntyre, Mary Ann Toomey, and Steven A. Rosenberg, National Cancer Institute, National Institutes of Health, Bethesda, MD; Adrian Bot, John Rossi, Allen Xue, Marika Sherman, and Arianne Perez, Kite Pharma, Santa Monica, CA; Tatyana Feldman, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; and Jonathan W. Friedberg, University of Rochester School of Medicine, Rochester, NY.

      Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD USA

      National Cancer Institute, Bethesda, MD;

      2016

      Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

      Stephanie L. Goff, Deborah E. Citrin, Robert P. Somerville, John R. Wunderlich, David N. Danforth, James C. Yang, Richard M. Sherry, Udai S. Kammula, Christopher A. Klebanoff, Marybeth S. Hughes, Nicholas P. Restifo, Michelle M. Langhan, Thomas E. Shelton, Lily Lu, Mei Li M. Kwong, Sadia Ilyas, Nicholas D. Klemen, Eden C. Payabyab, Kathleen E. Morton, Mary Ann Toomey, Seth M. Steinberg, Donald E. White, and Steven A. Rosenberg, National Cancer Institute, National Institutes of Health; Daniel A. Zlott, Clinical Center, National Institutes of Health, Bethesda, MD; and Mark E. Dudley, Novartis Institutes for BioMedical Research, Cambridge, MA.

      Center for Clinical Research, National Cancer Institute, Bethesda, MD, United States

      National Cancer Institute, NIH, MD, USA

      2015

      Surgery Branch and

      NIH/NCI, Bethesda, MD, USA

      All authors: National Cancer Institute, Bethesda, MD.

      2014

      Surgery Branch, National Cancer Institute, Bethesda, MD 20892

      National Cancer Institute Bethesda Maryland

      NCI, Bethesda, MD

      , E-mail:

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Steven Aaron Rosenberg is among the top experts in the world.
      Concept World rank
      aim antigens cells #1
      g2092 #1
      cd15int #1
      bcell antigen cd19 #1
      qrtpcr status #1
      dor 3 years #1
      expression mart1 #1
      identification nyeso1 #1
      mca mca 101 #1
      peptides gp100 #1
      vegfr2 car #1
      cultured clinical trials #1
      adoptive transfer patients #1
      lymphokines large quantities #1
      9 10 mart1 #1
      transfer autologous #1
      mtcr antibody development #1
      melanoma nos1 expression #1
      beta loss #1
      peptide patients #1
      experimental recombinant #1
      cells recognized #1
      tumor microenvironment tumor #1
      p53 expression recognition #1
      erk1 2 combination #1
      treatment interleukin2 #1
      lak cells patients #1
      oral irritation patients #1
      pulse sequences mri #1
      lymphocytes tumor #1
      ltx wbx #1
      cd8 cells dexamethasone #1
      nct00924326 #1
      1241170fold #1
      treatment il2 #1
      peptide wt1126 tcr #1
      immunochromatography rpm #1
      mca102 htnf #1
      lymphocytes adoptive #1
      secondary immunotherapy #1
      gp100 tumor #1
      gastrointestinal cancers melanoma #1
      adamts18 metalloproteinase #1
      acquisition effector function #1
      clinical responses patients #1
      interleukin2 liver #1
      mice lak cells #1
      melanoma tils #1
      pd1 pbl #1
      frameshifted products #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Steven Aaron Rosenberg

      KOL-Index: 17483

      BACKGROUND: Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and response rates of consecutively enrolled patients treated with a consistent regimen and assessed on an intention-to-treat basis have not been reported. We aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological correlates of response ...

      Known for 21 Patients | 1 Dose | Children Young Adults | Acute Lymphoblastic | Escalation Trial
      KOL-Index: 15950

      The alpha- and beta-chains of the TCR from a highly avid anti-gp100 CTL clone were isolated and used to construct retroviral vectors that can mediate high efficiency gene transfer into primary human lymphocytes. Expression of this TCR gene was confirmed by Western blot analysis, immunocytometric analysis, and HLA Ag tetramer staining. Gene transfer efficiencies of >50% into primary lymphocytes were obtained without selection for transduced cells using a method of prebinding retroviral ...

      Known for Tcr Gene | Tumor Antigen | Primary Human Lymphocytes | Transformed Cell | Gp100 Melanoma
      KOL-Index: 15411

      BACKGROUND: In a subset of patients with metastatic melanoma, T lymphocytes bearing the cell-surface marker CD8 (CD8+ T cells) can cause the regression of even large tumors. These antitumor CD8+ T cells recognize peptide antigens presented on the surface of tumor cells by major histocompatibility complex (MHC) class I molecules. The MHC class I molecule is a heterodimer composed of an integral membrane glycoprotein designated the alpha chain and a noncovalently associated, soluble ...

      Known for Beta 2 | Metastatic Melanoma | Immunotherapy Patients | Cell Lines | Messenger Rna
      KOL-Index: 14964

      Incubation of resting lymphoid cells with recombinant interleukin 2 (IL-2) in vitro leads to the generation of lymphokine activated killer (LAK) cells capable of lysing fresh tumor cell suspensions in short-term chromium-release assays. Our previous studies (7) have demonstrated that the injection of LAK cells plus low doses of recombinant IL-2 were capable of inhibiting the growth of pulmonary metastases. We have now explored the ability of high doses of recombinant IL-2, administered ...

      Known for Systemic Administration | Pulmonary Metastases | Recombinant Interleukin | Lak Cells | Antitumor Effects
      KOL-Index: 14648

      PURPOSE: Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from the transplant donor. DLIs frequently are not effective at eradicating malignancy and often cause graft-versus-host disease, a potentially lethal immune response against normal recipient tissues.

      METHODS: We conducted a clinical trial of allogeneic ...

      Known for Cell Transplantation | Host Disease | Allogeneic Hematopoietic | Lymphocytic Chronic | Cd19 Chimeric
      KOL-Index: 14464

      The recent identification of genes encoding melanoma-associated antigens has opened new possibilities for the development of cancer vaccines designed to cause the rejection of established tumors. To develop a syngeneic animal model for evaluating antigen-specific vaccines in cancer therapy, the murine homologues of the human melanoma antigens MART1 and gp100, which were specifically recognized by tumor-infiltrating lymphocytes from patients with melanoma, were cloned and sequenced from a ...

      Known for Human Melanoma | Murine Mart1 Gp100 | Immunization Mice | Cancer Vaccines | Mart1 Antigen
      KOL-Index: 14462

      BACKGROUND: Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma.

      METHODS: A randomized, double-blind, phase 2 trial was conducted comparing placebo with bevacizumab at doses of 3 and 10 mg per kilogram of body weight, given every two ...

      Known for Metastatic Renal Cancer | Endothelial Growth | Progression Disease | Humanized Bevacizumab Carcinoma | Monoclonal Antibodies
      KOL-Index: 14113

      PURPOSE: The E6 and E7 oncoproteins of HPV-associated epithelial cancers are in principle ideal immunotherapeutic targets, but evidence that T cells specific for these antigens can recognize and kill HPV(+) tumor cells is limited. We sought to determine whether TCR gene engineered T cells directed against an HPV oncoprotein can successfully target HPV(+) tumor cells.

      EXPERIMENTAL DESIGN: T-cell responses against the HPV-16 oncoproteins were investigated in a patient with an ongoing ...

      Known for Tcr Gene | Tumor Cells | Epithelial Cancer | Hpv16 E6 | Humans Lymphocytes
      KOL-Index: 13915

      PURPOSE: Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an effective cancer treatment for patients with metastatic melanoma. The NY-ESO-1 cancer/testis antigen, which is expressed in 80% of patients with synovial cell sarcoma and approximately 25% of patients with melanoma and common epithelial tumors, represents an attractive target for immune-based therapies. The current trial was carried out to evaluate the ability of adoptively transferred autologous T cells ...

      Known for Tumor Regression | Synovial Cell Sarcoma | Patients Melanoma | Immunotherapy Lymphocytes | Transduced Cells
      KOL-Index: 13854

      While much emphasis has been placed on the role of MHC class I-restricted CD8+ T cells in the recognition of tumor-specific antigens (Ag), evidence has accumulated that CD4+ T cells also play a critical role in the anti-tumor immune response. However, little information exists on the nature of MHC class II-restricted human tumor Ag. In an attempt to develop in vitro systems to characterize such Ag, we examined the ability of Epstein-Barr virus (EBV)-transformed B cells to present ...

      Known for Melanoma Antigens | Specific Cd4 | Tumor Cells | Mhc Class | Barr Virus

      Key People For Metastatic Melanoma

      Top KOLs in the world
      #1
      Dirk Schadendorf
      melanoma patients advisory consultancy braf v600
      #2
      Caroline Robert
      advanced melanoma braf v600 advisory consultancy
      #3
      Reinhard G Dummer
      metastatic melanoma cutaneous lymphomas advisory consultancy
      #4
      Jeffrey Alan Sosman
      metastatic melanoma renal cell solid tumors
      #5
      Jeffrey S Weber
      metastatic melanoma advisory consultancy complete resection
      #6
      John Munn Kirkwood
      metastatic melanoma adjuvant therapy advisory consultancy

      Surgery Branch, Center for Cancer Research, NCI, NIH, Bethesda, Maryland. | Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. | Surgery Branch, National Cancer Institute, Na

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.